British journal of cancer · 1996

Metabolic effects of pamidronate in patients with metastatic bone disease.

Название и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE

Аннотация

We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion. Twenty patients received a single infusion of pamidronate 120 mg for painful bone metastases. Ten out of these 20 patients also received a second infusion. They were evaluated at baseline, 2, 4 and 8 weeks after each infusion. A composite pain questionnaire, serum and urine tests were carried out at these time points. Bone resorption markers measured included urinary calcium, hydroxyproline and two new markers: pyridinoline and deoxypyridinoline. Reference values were defined by 20 healthy controls matched by age and sex. Pamidronate induced a profound fall in bone resorption with a maximal effect within the first month after therapy. Changes in urinary calcium levels were confounded by a rise of 100% in the parathyroid hormone levels. Before treatment, pyridinoline and deoxypyridinoline were increased in 70% of patients, while urinary calcium was increased in only 40% of them. Thirteen patients had a > or = 50% fall in deoxypyridinoline levels and were considered as biochemical responders. These patients had a mean reduction in pain score of about 30% of baseline levels, which was significantly higher than the seven non-biochemical responders. In conclusion, urinary calcium is not a precise marker of bone resorption. Deoxypyridinoline seems to be the most specific bone resorption marker in cancer patients. Biochemical responders have the most benefit from pamidronate in terms of pain relief. This suggests that patients may benefit from more potent or repeated infusions of bisphosphonates.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Blomqvist C. Elomaa I. Virkkunen P. Porkka L. Karonen S. L. Risteli L. Risteli J. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. 60 12 15 12 1987 2907 2912 Cancer 3315177 10.1002/1097-0142(19871215)60:12<2907::aid-cncr2820601211>3.0.co;2-b

Blumsohn A. Hannon R. A. Eastell R. Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. 41 2 2 1995 318 319 Clin Chem 7874787

Blumsohn A. Naylor K. E. Assiri A. M. Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. 41 11 11 1995 1592 1598 Clin Chem 7586548

Body J. J. Delmas P. D. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. 74 3 3 1992 471 475 J Clin Endocrinol Metab 1740478 10.1210/jcem.74.3.1740478

Campbell F. C. Blamey R. W. Woolfson A. M. Elston C. W. Hosking D. J. Calcium excretion (CaE) in metastatic breast cancer. 70 4 4 1983 202 204 Br J Surg 6831170 10.1002/bjs.1800700405

Coleman R. E. Houston S. James I. Rodger A. Rubens R. D. Leonard R. C. Ford J. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. 65 5 5 1992 766 768 Br J Cancer PMC1977378 1586605 10.1038/bjc.1992.161

Coleman R. E. Rubens R. D. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. 56 4 10 1987 465 469 Br J Cancer PMC2001821 3689664 10.1038/bjc.1987.225

Coleman R. E. Whitaker K. B. Moss D. W. Mashiter G. Fogelman I. Rubens R. D. Biochemical prediction of response of bone metastases to treatment. 58 2 8 1988 205 210 Br J Cancer PMC2246751 3262366 10.1038/bjc.1988.194

Colwell A. Russell R. G. Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. 23 6 6 1993 341 349 Eur J Clin Invest 8344334 10.1111/j.1365-2362.1993.tb02034.x

Eyre D. R. Koob T. J. Van Ness K. P. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. 137 2 3 1984 380 388 Anal Biochem 6731820 10.1016/0003-2697(84)90101-5

Flanagan A. M. Chambers T. J. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. 6 1 4 1989 33 43 Bone Miner 2526673 10.1016/0169-6009(89)90021-4

Garnero P. Gineyts E. Riou J. P. Delmas P. D. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. 79 3 9 1994 780 785 J Clin Endocrinol Metab 8077361 10.1210/jcem.79.3.8077361

Garnero P. Grimaux M. Seguin P. Delmas P. D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. 9 2 2 1994 255 264 J Bone Miner Res 8140939 10.1002/jbmr.5650090215

Hanson D. A. Weis M. A. Bollen A. M. Maslan S. L. Singer F. R. Eyre D. R. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. 7 11 11 1992 1251 1258 J Bone Miner Res 1466251 10.1002/jbmr.5650071119

Lahtinen R. Laakso M. Palva I. Virkkunen P. Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. 340 8827 31 10 1992 1049 1052 Lancet 1357451 10.1016/0140-6736(92)93075-x

Li F. Pitt P. I. Sherwood R. Barrett J. Houghton J. Parsons V. Moniz C. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. 23 9 9 1993 566 571 Eur J Clin Invest 8243528 10.1111/j.1365-2362.1993.tb00967.x

Lipton A. Demers L. Daniloff Y. Curley E. Hamilton C. Harvey H. Witters L. Seaman J. Van der Giessen R. Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. 39 4 4 1993 614 618 Clin Chem 8472354

Löwik C. W. van der Pluijm G. van der Wee-Pals L. J. van Treslong-De Groot H. B. Bijvoet O. L. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. 3 2 4 1988 185 192 J Bone Miner Res 3213614 10.1002/jbmr.5650030210

Martoni A. Guaraldi M. Camera P. Biagi R. Marri S. Beghé F. Pannuti F. Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton. 48 2 1991 97 101 Oncology 1825515 10.1159/000226904

O'Rourke N. McCloskey E. Houghton F. Huss H. Kanis J. A. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. 13 4 4 1995 929 934 J Clin Oncol 7707121 10.1200/JCO.1995.13.4.929

Paterson A. H. Powles T. J. Kanis J. A. McCloskey E. Hanson J. Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. 11 1 1 1993 59 65 J Clin Oncol 8418243 10.1200/JCO.1993.11.1.59

Pecherstorfer M. Schilling T. Janisch S. Woloszczuk W. Baumgartner G. Ziegler R. Ogris E. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. 34 7 7 1993 1039 1044 J Nucl Med 8315476

Pecherstorfer M. Zimmer-Roth I. Schilling T. Woitge H. W. Schmidt H. Baumgartner G. Thiébaud D. Ludwig H. Seibel M. J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. 80 1 1 1995 97 103 J Clin Endocrinol Metab 7829646 10.1210/jcem.80.1.7829646

Purohit O. P. Anthony C. Radstone C. R. Owen J. Coleman R. E. High-dose intravenous pamidronate for metastatic bone pain. 70 3 9 1994 554 558 Br J Cancer PMC2033374 8080746 10.1038/bjc.1994.344

Reid I. R. Wattie D. J. Evans M. C. Gamble G. D. Stapleton J. P. Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. 79 6 12 1994 1595 1599 J Clin Endocrinol Metab 7989461 10.1210/jcem.79.6.7989461

Rosalki S. B. Foo A. Y. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. 30 7 7 1984 1182 1186 Clin Chem 6547374

Thiébaud D. Leyvraz S. von Fliedner V. Perey L. Cornu P. Thiébaud S. Burckhardt P. Treatment of bone metastases from breast cancer and myeloma with pamidronate. 27 1 1991 37 41 Eur J Cancer 1826438 10.1016/0277-5379(91)90056-j

van Holten-Verzantvoort A. T. Kroon H. M. Bijvoet O. L. Cleton F. J. Beex L. V. Blijham G. Hermans J. Neijt J. P. Papapoulos S. E. Sleeboom H. P. Palliative pamidronate treatment in patients with bone metastases from breast cancer. 11 3 3 1993 491 498 J Clin Oncol 7680374 10.1200/JCO.1993.11.3.491

Metabolic effects of pamidronate in patients with metastatic bone disease.

Ошибки и ограничения

Аннотация